Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
相关临床试验
8
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
25.0%
已完成
1
12.5%
招募中
2
25.0%
暂停
1
12.5%
终止
1
12.5%
Unknown
1
12.5%
暂无批准数据
- Apollomics plans to submit an Investigational New Drug Application for accelerated approval of vebreltinib for second-line NSCLC treatment with c-MET amplification in the first half of 2027, based on FDA guidance. - The company's lead asset vebreltinib has already received approval in China for three indications including METex14 skipping NSCLC and MET-amplified NSCLC, marking it as the first c-MET inhibitor approved for certain conditions. - Following a strategic turnaround with new management, Apollomics reduced operating expenses by 64% year-over-year to $19.8 million in 2025 while advancing global Phase 2 studies with over 282 subjects enrolled. - The company generated $8.5 million in revenue in 2025 from a licensing agreement with LaunXP for vebreltinib development in Asia, compared to zero revenue in 2024.
- DelveInsight's analysis reveals a robust acute myeloid leukemia pipeline with over 100 companies actively developing 150+ therapeutic candidates across various clinical stages. - Recent regulatory milestones include FDA approval of KOMZIFTI (ziftomenib) for relapsed/refractory NPM1-mutated AML and priority review acceptance for revumenib, both representing first-in-class menin inhibitors. - The pipeline features diverse therapeutic approaches including targeted therapies like isocitrate dehydrogenase inhibitors, immunotherapies, and novel mechanisms of action addressing unmet medical needs in this aggressive blood cancer.
- Apollomics' Phase 3 trial of uproleselan in China did not meet its primary endpoint, showing no significant benefit in overall survival for patients with relapsed or refractory AML. - The median overall survival in the uproleselan arm was 9.3 months, compared to 14.3 months in the chemotherapy-only arm, indicating a potential detriment with the addition of uproleselan. - Due to the trial's failure and a previous unsuccessful global Phase 3 trial, Apollomics is discontinuing the uproleselan program, with remaining expenses expected to be under $500,000. - Apollomics will focus on its lead program, vebreltinib (APL-101), a c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors.
